Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
CALGARY, Alberta, Dec. 14, 2017 -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements and Management’s Discussion & Analysis for the quarter ended October 31, 2017 with Canadian securities regulatory authorities.
Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing [email protected]
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on Twitter: https://twitter.com/resverlogix_rvx
For further information please contact:
Investor Relations
Email: [email protected]
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
